The cluster headache market size valued for $356.00 million in 2021 and is estimated to reach $522.98 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.
Cluster headache is the most common type of the primary headache known as trigeminal autonomic cephalgia (TACs). Cluster headache is characterized by attacks of very severe, unilateral headache lasting 15-180 minutes, up to several times per day. It is distinguished by the severe nature of the pain, length of attacks, and presence of cranial autonomic symptoms such as lacrimation and conjunctival injection. Attacks often cluster and can occur in series for weeks or months at a time, followed by a period of complete remission. This significant pain is accompanied by increased suicidality during cluster periods, particularly during the time of the headache.
The driving factors for cluster headache market are increase in number of patients suffering from cluster headache, and rise in investments for development of effective medications for cluster headache. Moreover, surge in incidences of neurological disorders such as cluster headache results in demand of effective medications for treating headache disorders, thus increasing incidences of cluster headache is expected to drive the growth of the market. For instance, according to article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache in Norway was found to be 48.6 per 100,000/year, thereby driving the growth of the market. In addition, increase in number of pipeline medications for treating cluster headache that is anticipated to receive regulatory approval in the upcoming years is projected to propel market expansion.
Further, various grants and fellowships are provided by government and private institutions for research and development activities involving headache disorders such as cluster headache, which further propels the market expansion. For instance, according to report of International Headache Society (IHS) 2022, stated that, IHS offers total 20-30 fellowships such as ‘IHS Junior Research Grant’ to support innovative and impactful research from young investigators, promote the career of young investigators in the field of headache and increase the knowledge base of headache disorders, thus such available fellowships for R&D in headache disorders is anticipated to drive the growth of the market.
However, lengthy drug approval process and strict regulatory pathways are the factors that restrain the growth of the market. In addition, absence of favorable reimbursement policies is also expected to constrain the growth of the market.
Further, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.
The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Cluster headache is the most common type of the primary headache known as trigeminal autonomic cephalgia (TACs). Cluster headache is characterized by attacks of very severe, unilateral headache lasting 15-180 minutes, up to several times per day. It is distinguished by the severe nature of the pain, length of attacks, and presence of cranial autonomic symptoms such as lacrimation and conjunctival injection. Attacks often cluster and can occur in series for weeks or months at a time, followed by a period of complete remission. This significant pain is accompanied by increased suicidality during cluster periods, particularly during the time of the headache.
The driving factors for cluster headache market are increase in number of patients suffering from cluster headache, and rise in investments for development of effective medications for cluster headache. Moreover, surge in incidences of neurological disorders such as cluster headache results in demand of effective medications for treating headache disorders, thus increasing incidences of cluster headache is expected to drive the growth of the market. For instance, according to article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache in Norway was found to be 48.6 per 100,000/year, thereby driving the growth of the market. In addition, increase in number of pipeline medications for treating cluster headache that is anticipated to receive regulatory approval in the upcoming years is projected to propel market expansion.
Further, various grants and fellowships are provided by government and private institutions for research and development activities involving headache disorders such as cluster headache, which further propels the market expansion. For instance, according to report of International Headache Society (IHS) 2022, stated that, IHS offers total 20-30 fellowships such as ‘IHS Junior Research Grant’ to support innovative and impactful research from young investigators, promote the career of young investigators in the field of headache and increase the knowledge base of headache disorders, thus such available fellowships for R&D in headache disorders is anticipated to drive the growth of the market.
However, lengthy drug approval process and strict regulatory pathways are the factors that restrain the growth of the market. In addition, absence of favorable reimbursement policies is also expected to constrain the growth of the market.
Further, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.
The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cluster headache market analysis from 2021 to 2031 to identify the prevailing cluster headache market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cluster headache market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cluster headache market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Drug class
- Ergot derivatives
- Calcium channel blockers
- Triptans
By Distribution channel
- Hospital pharmacies
- Drug stores and retail pharmacies
By Type
- Episodic
- Chronic
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Dr. Reddy’s Laboratories Ltd.
- FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- GlaxoSmithKline plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Arrotex Australia Group
- Grunenthal
- Eli Lilly and Company
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cluster headache
3.4.1.2. Development of novel therapeutics for treatment of cluster headache
3.4.1.3. Increase in awareness about cluster headache
3.4.2. Restraints
3.4.2.1. Side effects associated with medications used for cluster headache
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CLUSTER HEADACHE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Episodic
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chronic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CLUSTER HEADACHE MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Ergot derivatives
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Calcium channel blockers
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Triptans
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: CLUSTER HEADACHE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Drug class
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Drug class
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Drug class
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Drug class
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Drug class
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Drug class
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Drug class
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Drug class
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Drug class
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Drug class
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Drug class
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Drug class
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Drug class
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Drug class
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Drug class
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Drug class
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Drug class
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Drug class
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Drug class
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Drug class
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Drug class
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Drug class
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Drug class
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Dr. Reddy’s Laboratories Ltd.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Eli Lilly and Company
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Novartis AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Pfizer Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Arrotex Australia Group
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Key strategic moves and developments
9.10. Grunenthal
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
Table 01. Global Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 02. Cluster Headache Market for Episodic, by Region, 2021-2031 (Revenue, $Million)
Table 03. Cluster Headache Market for Chronic, by Region, 2021-2031 (Revenue, $Million)
Table 04. Global Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 05. Cluster Headache Market for Ergot Derivatives, by Region, 2021-2031 (Revenue, $Million)
Table 06. Cluster Headache Market for Calcium Channel Blockers, by Region, 2021-2031 (Revenue, $Million)
Table 07. Cluster Headache Market for Triptans, by Region, 2021-2031 (Revenue, $Million)
Table 08. Cluster Headache Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 09. Global Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 10. Cluster Headache Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 11. Cluster Headache Market for Drug Stores and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 12. Cluster Headache Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 13. Cluster Headache Market, by Region, 2021-2031 (Revenue, $Million)
Table 14. North America Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 15. North America Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 16. North America Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 17. North America Cluster Headache Market, by Country, 2021-2031 (Revenue, $Million)
Table 18. U.S. Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 19. U.S. Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 20. U.S. Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 21. Canada Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 22. Canada Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 23. Canada Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 24. Mexico Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 25. Mexico Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 26. Mexico Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 27. Europe Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 28. Europe Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 29. Europe Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Europe Cluster Headache Market, by Country, 2021-2031 (Revenue, $Million)
Table 31. Germany Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 32. Germany Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 33. Germany Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 34. France Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 35. France Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 36. France Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 37. UK Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 38. UK Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 39. UK Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 40. Italy Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 41. Italy Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 42. Italy Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 43. Spain Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 44. Spain Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 45. Spain Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 46. Rest of Europe Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 49. Asia-Pacific Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Cluster Headache Market, by Country, 2021-2031 (Revenue, $Million)
Table 53. Japan Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 54. Japan Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 55. Japan Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. China Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 57. China Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 58. China Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 59. India Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 60. India Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 61. India Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 62. Australia Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 63. Australia Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 64. Australia Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 65. South Korea Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 66. South Korea Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 67. South Korea Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 68. Rest of Asia-Pacific Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 71. LAMEA Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Cluster Headache Market, by Country, 2021-2031 (Revenue, $Million)
Table 75. Brazil Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 76. Brazil Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 77. Brazil Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 78. Saudi Arabia Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 81. South Africa Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 82. South Africa Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 83. South Africa Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 84. Rest of LAMEA Cluster Headache Market, by Type, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Cluster Headache Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Cluster Headache Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 87. Dr. Reddy's Laboratories Ltd.: Key Executives
Table 88. Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 89. Dr. Reddy's Laboratories Ltd.: Product Segments
Table 90. Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 91. Eli Lilly and Company: Key Executives
Table 92. Eli Lilly and Company: Company Snapshot
Table 93. Eli Lilly and Company: Product Segments
Table 94. Eli Lilly and Company: Product Portfolio
Table 95. Eli Lilly and Company: Key Strategies
Table 96. Fresenius SE & Co. KGaA (Fresenius Kabi): Key Executives
Table 97. Fresenius SE & Co. KGaA (Fresenius Kabi): Company Snapshot
Table 98. Fresenius SE & Co. KGaA (Fresenius Kabi): Product Segments
Table 99. Fresenius SE & Co. KGaA (Fresenius Kabi): Product Portfolio
Table 100. GlaxoSmithKline PLC: Key Executives
Table 101. GlaxoSmithKline PLC: Company Snapshot
Table 102. GlaxoSmithKline PLC: Product Segments
Table 103. GlaxoSmithKline PLC: Product Portfolio
Table 104. Novartis AG: Key Executives
Table 105. Novartis AG: Company Snapshot
Table 106. Novartis AG: Product Segments
Table 107. Novartis AG: Product Portfolio
Table 108. Pfizer Inc.: Key Executives
Table 109. Pfizer Inc.: Company Snapshot
Table 110. Pfizer Inc.: Product Segments
Table 111. Pfizer Inc.: Product Portfolio
Table 112. Sun Pharmaceutical Industries Ltd.: Key Executives
Table 113. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 114. Sun Pharmaceutical Industries Ltd.: Product Segments
Table 115. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 116. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 117. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 118. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 119. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 120. Arrotex Australia Group: Key Executives
Table 121. Arrotex Australia Group: Company Snapshot
Table 122. Arrotex Australia Group: Product Segments
Table 123. Arrotex Australia Group: Product Portfolio
Table 124. Arrotex Australia Group: Key Strategies
Table 125. Grunenthal: Key Executives
Table 126. Grunenthal: Company Snapshot
Table 127. Grunenthal: Product Segments
Table 128. Grunenthal: Product Portfolio
List of Figures
Figure 01. Cluster Headache Market, 2021-2031
Figure 02. Segmentation of Cluster Headache Market, 2021-2031
Figure 03. Top Investment Pockets in Cluster Headache Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalcluster Headache Market
Figure 10. Cluster Headache Market, by Type, 2021(%)
Figure 11. Comparative Share Analysis of Cluster Headache Market for Episodic, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Cluster Headache Market for Chronic, by Country 2021-2031(%)
Figure 13. Cluster Headache Market, by Drug Class, 2021(%)
Figure 14. Comparative Share Analysis of Cluster Headache Market for Ergot Derivatives, by Country 2021-2031(%)
Figure 15. Comparative Share Analysis of Cluster Headache Market for Calcium Channel Blockers, by Country 2021-2031(%)
Figure 16. Comparative Share Analysis of Cluster Headache Market for Triptans, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Cluster Headache Market for Others, by Country 2021-2031(%)
Figure 18. Cluster Headache Market, by Distribution Channel, 2021(%)
Figure 19. Comparative Share Analysis of Cluster Headache Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 20. Comparative Share Analysis of Cluster Headache Market for Drug Stores and Retail Pharmacies, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Cluster Headache Market for Others, by Country 2021-2031(%)
Figure 22. Cluster Headache Market by Region, 2021
Figure 23. U.S. Cluster Headache Market, 2021-2031 ($Million)
Figure 24. Canada Cluster Headache Market, 2021-2031 ($Million)
Figure 25. Mexico Cluster Headache Market, 2021-2031 ($Million)
Figure 26. Germany Cluster Headache Market, 2021-2031 ($Million)
Figure 27. France Cluster Headache Market, 2021-2031 ($Million)
Figure 28. UK Cluster Headache Market, 2021-2031 ($Million)
Figure 29. Italy Cluster Headache Market, 2021-2031 ($Million)
Figure 30. Spain Cluster Headache Market, 2021-2031 ($Million)
Figure 31. Rest of Europe Cluster Headache Market, 2021-2031 ($Million)
Figure 32. Japan Cluster Headache Market, 2021-2031 ($Million)
Figure 33. China Cluster Headache Market, 2021-2031 ($Million)
Figure 34. India Cluster Headache Market, 2021-2031 ($Million)
Figure 35. Australia Cluster Headache Market, 2021-2031 ($Million)
Figure 36. South Korea Cluster Headache Market, 2021-2031 ($Million)
Figure 37. Rest of Asia-Pacific Cluster Headache Market, 2021-2031 ($Million)
Figure 38. Brazil Cluster Headache Market, 2021-2031 ($Million)
Figure 39. Saudi Arabia Cluster Headache Market, 2021-2031 ($Million)
Figure 40. South Africa Cluster Headache Market, 2021-2031 ($Million)
Figure 41. Rest of LAMEA Cluster Headache Market, 2021-2031 ($Million)
Figure 42. Top Winning Strategies, by Year
Figure 43. Top Winning Strategies, by Development
Figure 44. Top Winning Strategies, by Company
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap: Cluster Headache Market
Figure 48. Top Player Positioning, 2021
Figure 49. Dr. Reddy's Laboratories Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 50. Dr. Reddy's Laboratories Ltd.: Revenue Share by Segment, 2021 (%)
Figure 51. Dr. Reddy's Laboratories Ltd.: Revenue Share by Region, 2021 (%)
Figure 52. Eli Lilly and Company: Net Revenue, 2019-2021 ($Million)
Figure 53. Eli Lilly and Company: Revenue Share by Region, 2021 (%)
Figure 54. Fresenius SE & Co. KGaA (Fresenius Kabi): Net Revenue, 2019-2021 ($Million)
Figure 55. Fresenius SE & Co. KGaA (Fresenius Kabi): Revenue Share by Segment, 2021 (%)
Figure 56. Fresenius SE & Co. KGaA (Fresenius Kabi): Revenue Share by Region, 2021 (%)
Figure 57. GlaxoSmithKline PLC: Net Sales, 2019-2021 ($Million)
Figure 58. GlaxoSmithKline PLC: Revenue Share by Segment, 2021 (%)
Figure 59. GlaxoSmithKline PLC: Revenue Share by Region, 2021 (%)
Figure 60. Novartis AG: Net Sales, 2019-2021 ($Million)
Figure 61. Novartis AG: Revenue Share by Segment, 2021 (%)
Figure 62. Novartis AG: Revenue Share by Region, 2021 (%)
Figure 63. Pfizer Inc.: Net Revenue, 2019-2021 ($Million)
Figure 64. Pfizer Inc.: Revenue Share by Segment, 2021 (%)
Figure 65. Pfizer Inc.: Revenue Share by Region, 2021 (%)
Figure 66. Sun Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 67. Sun Pharmaceutical Industries Ltd.: Revenue Share by Region, 2021 (%)
Figure 68. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 69. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2021 (%)
Figure 70. Grunenthal: Net Revenue, 2019-2021 ($Million)
Figure 71. Grunenthal: Revenue Share by Segment, 2021 (%)
Figure 72. Grunenthal: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, 'Cluster Headache Market,' the cluster headache market size was valued at $356.00 million in 2021, and is estimated to reach $522.98 million by 2031, growing at a CAGR of 3.9% from 2022 to 2031.Cluster headache is a primary headache disorder that leads to attacks of excruciating unilateral head pain with ipsilateral cranial autonomic features. These attacks can cluster, with frequent occurrences for weeks or months at a time followed by a period of complete remission.
Key factors driving the growth of the cluster headache market are rise in prevalence of headache disorders, availability of advanced technologies for diagnosis of cluster headache, and increase in research activities for development of novel therapeutics. For instance, article published in National Library of Medicine 2020, reported that genetic factor is thought to increase the chances of developing cluster headache, and can affect multiple members of a family. The prevalence of cluster headache is estimated to be around 0.1% globally, with a higher incidence in males compared to females. The increasing recognition of the condition as a separate entity from other types of headaches has led to a growing demand for effective treatments.
In addition, prevalence of cluster headache is more in men owing to lifestyle habits such as smoking, alcohol use. Thus, rise in number of smokers results in higher prevalence of cluster headache.
For instance, article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache is more in men owing to smoking habit, thus rise in smoking habit is expected to contribute toward the growth of the market. Furthermore, many universities are sponsoring research studies related to headache disorders for development of novel therapeutics, thus driving the growth of cluster headache market. In Germany, many universities are sponsoring research studies for development of novel medications for treatment of cluster headache. For instance, report of U.S. National Library of Medicine - Clinical trials 2022, stated that, Charite University (Germany) sponsored clinical trial study to determine efficacy of erenumab in chronic cluster headache. Thus, such sponsored studies are anticipated to drive the growth of the market.
Further, the increasing awareness and education about cluster headache among healthcare providers and the general public has led to an increase in early diagnosis and treatment, further driving the market for treatments for the condition. For instance, according to report of European Migraine and Headache Alliance 2022, stated that, every year campaign is organized by government to raise awareness of headache-related issues throughout Europe, promoting early diagnosis and access to appropriate treatment.
The market also offers growth opportunities to the key players in the market. Many developing regions such India and Brazil offer lucrative opportunities to key players of cluster headache market owing to high population base, increase in demand of novel formulations for treating cluster headache and increase in healthcare spending. In addition, government sponsored research studies regarding cluster headache in various countries and medical tourism fuels the growth of cluster headache market.
The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, corticosteroids, calcium channel blockers, triptans, antiepileptic drugs and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Arrotex Australia Group, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. The players in the market have been actively engaged in the adoption various Strategies such product approval, product launch, and merger to remain competitive and gain advantage over the competitors in the market. For instance, in July 2019, Eli Lilly and Company received U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.
Key Market Insights
- On the basis of type, the episodic segment was highest contributor to the market in 2021.
- On the basis of drug class, the calcium channel blockers segment dominated the market in terms of revenue in 2021. However, the others segment is anticipated to grow at the highest CAGR during the forecast period.
- On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- GlaxoSmithKline plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Arrotex Australia Group
- Grunenthal
- Eli Lilly and Company
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
